Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Adults >16 years of age

• Dry eye patients

• Subject with history of less than 12 weeks of initial RESTASIS® treatment

• Subject started second trial of RESTASIS® treatment prior to June 1, 2008

• First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment

Exclusion Criteria:

• Patients with Contact Lens Intolerance

• Patients with Ocular Rosacea